Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

De Benedetti, Fabrizio; I Brunner, Hermine; Ruperto, Nicolino; Kenwright, Andrew; Wright, Stephen; Calvo, Inmaculada; Cuttica, Ruben; Ravelli, Angelo; Schneider, Rayfel; Woo, Patricia; Wouters, Carine; Xavier, Ricardo; Zemel, Lawrence; Baildam, Eileen; Burgos-Vargas, Ruben; Dolezalova, Pavla; M Garay, Stella; Merino, Rosa; Joos, Rik; Grom, Alexei; Wulffraat, Nico; Zuber, Zbigniew; Zulian, Francesco; Lovell, Daniel; Martini, Alberto; , PRINTO; , PRCSG

doi:10.1056/NEJMoa1112802

Public

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

Shared by NobleBlocks on Dec 20, 2012 • 12:00 AM UTC

Authors:

Fabrizio De Benedetti

Hermine I Brunner

Nicolino Ruperto

Abstract

BACKGROUND: Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA; treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. METHODS: We randomly assigned 112 children, 2 to 17 years of age, with active systemic JIA (duration of ≥6 months and inad...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!